High-risk surgically resected pediatric melanoma and adjuvant interferon therapy

Pediatric Blood and Cancer

Volumn 44, Issue 5, 2005, Pages 441-448

  Chao, Mwe Mwe ^a   Schwartz, Jennifer L ^a   Wechsler, Daniel S ^a   Thornburg, Courtney D ^a   Griffith, Kent A ^a   Williams, James A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

High risk melanoma; Interferon alpha; Pediatric melanoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DACARBAZINE; RECOMBINANT ALPHA2B INTERFERON; TECHNETIUM SULFUR COLLOID TC 99M;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER SURGERY; CELL PROLIFERATION; CONSTIPATION; DEPRESSION; DIARRHEA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INFECTION; JUVENILE MELANOMA; LIVER TOXICITY; LYMPH NODE DISSECTION; MALIGNANT TRANSFORMATION; MELANOMA; MYALGIA; NAUSEA; NEUTROPENIA; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN SURGERY; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERONS; MALE; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 18144403503     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20168     Document Type: Review

References (49)

1. National Cancer Institute: Annual cancer statistics review, including cancer trends, 1950-1985. Washington DC: US Dept of Health and Human Services, NIH publication 1988:88-2789.
2. Surveillance, Epidemiology, and End Results (SEER). Cancer statistics review 1973-1999. National Cancer Institute. Accessed October 7, 2002. seer.cancer.gov/csr/1973-1999/overview.pdf
3. Jemal A, Murray T, Samuels A, et al. Cancer statistics. CA Cancer J Clin 2003;53:5-26.
4. Rigel DS, Carucci JA. Malignant melanoma: Prevention, early detection, and treatment in the 21st century. CA Cancer J Clin 2000;50:215-236; quiz 237-240.
5. Ruiz-Maldonado R, del Rosario Barona-Mazuera M, Hidalgo-Galvan LR, et al. Giant congenital melanocytic nevi, neurocutaneous melanosis and neurological alterations. Dermatology 1997;195: 125-128.
6. Ceballos PI, Ruiz-Maldonado R, Mihm MC, Jr. Melanoma in children. N Engl J Med 1995;332:656-662.
7. Williams ML, Pennella R. Melanoma, melanocytic nevi, and other melanoma risk factors in children. J Pediatr 1994;124:833-845.
8. Marghoob AA, Schoenbach SP, Kopf AW, et al. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study. Arch Dermatol 1996;132:170-175.
9. Reintgen DS, Vollmer R, Seigler HF. Juvenile malignant melanoma. Surg Gynecol Obstet 1989;168:249-253.
10. Chun K, Vazquez M, Sanchez JL. Malignant melanoma in children. Int J Dermatol 1993;32:41-43.
11. Rao BN, Hayes FA, Pratt CB, et al. Malignant melanoma in children: Its management and prognosis. J Pediatr Surg 1990;25: 198-203.
12. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
13. American Joint Committee on Cancer (AJCC). Cancer Staging Manual and Handbook, 6th Edition.
14. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988;318:1159-1162.
15. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438-441.
16. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001;8:101-108.
17. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 1998;5:322-328.
18. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
19. Gershenwald JE, Tseng CH, Thompson W, et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 1998;124:203-210.
20. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983.
21. Cochran AJ, Balda BR, Starz H, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000;89:236-241.
22. Sondak VK, Wolfe JA. Adjuvant therapy for melanoma. Curr Opin Oncol 1997;9:189-204.
23. Sondak VK. Adjuvant therapy for melanoma. Cancer J 2001; 7(Suppl 1):S24-S27.
24. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
25. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18: 2444-2458.
26. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/ S9512/C509801. J Clin Oncol 2001;19:2370-2380.
27. Philip PA, Flaherty LE. Biochemotherapy for melanoma. Curr Oncol Rep 2000;2:314-321.
28. Thompson LW, Brinckerhoff L, Slingluff CL, Jr. Vaccination for melanoma. Curr Oncol Rep 2000;2:292-299.
29. McMasters KM, Sondak VK, Lotze MT, et al. Recent advances in melanoma staging and therapy. Ann Surg Oncol 1999;6:467-475.
30. INTRON. A interferon alfa-2b, recombinant for injection (package insert). Kenilworth, NJ: Schering Corporation.
31. Cancer Therapy Evaluation Program, Common Toxicity Criteria Version 2.0, National Cancer Institute. Accessed October 7, 2002. http://ctep.cancer.gov/ forms/CTCManual_v4_10-4-99.pdf
32. Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002;20:3703-3718.
33. Tate PS, Ronan SG, Feucht KA, et al. Melanoma in childhood and adolescence: Clinical and pathological features of 48 cases. J Pediatr Surg 1993;28:217-222.
34. MacKie RM. Incidence, risk factors and prevention of melanoma. Eur J Cancer 1998;34(Suppl 3):S3-S6.
35. Elwood JM, Jopson J. Melanoma and sun exposure: An overview of published studies. Int J Cancer 1997;73:198-203.
36. Katsambas A, Nicolaidou E. Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology. Arch Dermatol 1996;132:444-450.
37. Schwartz JL, Wang TS, Hamilton TA, et al. Thin primary cutaneous melanomas: Associated detection patterns, lesion characteristics, and patient characteristics. Cancer 2002;95:1562-1568.
38. Handfield-Jones SE, Smith NP. Malignant melanoma in childhood. Br J Dermatol 1996;134:607-616.
39. Barnhill RL, Flotte TJ, Fleischli M, et al. Cutaneous melanoma and atypical Spitz tumors in childhood. Cancer 1995;76:1833-1845.
40. Barnhill RL. Childhood melanoma. Semin Diagn Pathol 1998;15: 189-194.
41. Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/ tumors: Lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 1999;30:513-520.
42. Spitz S. Melanomas of childhood. Am J Pathol 1948;24:591-609.
43. Piepkorn M. On the nature of histologic observations: The case of the Spitz nevus. J Am Acad Dermatol 1995;32:248-254.
44. Spatz A, Calonje E, Handfield-Jones S, et al. Spitz tumors in children: A grading system for risk stratification. Arch Dermatol 1999;135:282-285.
45. Su LD, Fullen DR, Sondak VK, et al. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: A report on 18 patients. Cancer 2003;97:499-507.
46. Johnson TM, Chang A, Redman B, et al. Management of melanoma with a multidisciplinary melanoma clinic model. J Am Acad Dermatol 2000;42:820-826.
47. Zuckerman R, Maier JP, Guiney WB, Jr., et al. Pediatric melanoma: Confirming the diagnosis with sentinel node biopsy. Ann Plast Surg 2001;46:394-399.
48. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant Interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-2783.
49. Cascinelli N, Santinami M. Excision of primary melanoma should allow primary closure of the wound. Recent Results Cancer Res 1995;139:317-321.